We aim to provide recommendations on the treatment of tardive dyskinesia [31] the aan guidelines emphasize the importance of early recognition, regular monitoring, and a tailored approach to the management of td, balancing the need for. Vmat2, vesicular monoamine transporter 2 * level a is the strongest recommendation, established as effective, based on at least 2 consistent class i studies Level b refers to probably effective treatment, derived from at least 1 class i study or 2 consistent class ii studies. We performed a systematic review of studies of the treatment of tardive dyskinesia
Studies were rated for methodological quality. No continue maintenance treatment s eve re medical director case review deutetrabenazine3 valbenazine3 additional notes I if patient is on a first generation antipsychotic, trial of a second generation antipsychotic with less dopaminergic activity may be considered 2when choosing treatment option for td, consider collaborative discussion. These medications work by regulating the release of dopamine in the brain, which helps reduce the in From the guidelines tardive dyskinesia is best treated with a reversible inhibitor of the vesicular monoamine transporter 2 (vmat2) for patients with moderate to severe or disabling symptoms associated with antipsychotic therapy
